Strides Arcolab receives USFDA approval for 2 more products
Strides Arcolab Limited (“Strides”) today announced receipt of 2 ANDA approvals for Dexamethasone Injection USP, 4mg/ml, (1ml Single-dose Vials, 20mg /5 ml, 120 mg /30 ml Multipledose Vials) and Dexamethasone Sodium Phosphate Injection USP, 10 mg /ml, (10 ml Multiple-dose Vials).
The products are licensed to Akorn-Strides, LLC, which is a Joint Venture that was formed in 2004 by Akorn Inc [NASDAQ: AKRX] and Strides Arcolab Limited [NSE:STAR, BSE: 532531] Ravi Seth, Chief Executive Officer- International Operations of Strides stated: We are pleased to announce that the Akorn Strides partnership has now received eleven ANDA approvals of the 18 filed till date and commercialization in case of some of these products has already commenced effective Q3, 2008.
Tags: calls, daytrading, free calls, intraday, tips
Similar Posts:
Latest Query
- by Sam
Search Our Archives
Research Desk
- Stocks Trading above their 50 day moving average - DMA In Stock Research
- Download free Ebooks based on Technical Analysis In Personal Training
- TOP 100 Stocks with the Highest P/E as on July 14th, 2013 In Stock Research
- TOP 100 Stocks with the Lowest P/E as on July 14th, 2013 In Stock Research
- Charting Pathsala - Your guide to Techincals In Technical Analysis